Bryan, Garnier & Co supports France Biotech’ “French Life Sciences Days” in New-York on June, 25th & 26th, 2014
PARIS, June, 18th, 2014 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, will be sponsoring the “French Life Sciences Days” that will be held in New-York on June, 25th & 26th, 2014, in partnership with France Biotech.
edition of “French Life Sciences Days” initiated by France Biotech aims at
fostering and boosting the connections between French public companies and
investors worldwide in an effort to facilitate exchanges and demonstrate the
solidity of French financial community. The event will be held in New York on
June, 25th & 26th, 2014.
Garnier & Co, joins the sponsorship committee as a partner of France
Biotech, along with Société Générale, Invest Security, Deloitte, NewCap
and BusinessWire, in order to support entrepreneurs in
the life sciences. Bryan, Garnier & Co, which
tops the European investment banking league tables in the European biopharma
and medtech markets, is also, through Bryan Garnier Securities LLC, one of the
most active broker-dealers in the US promoting European healthcare growth
companies, Bryan, Garnier & Co’s presentation is available
major event will bring together French biotech and medtech companies listed on
the NYSE Euronext to exchange with members of the French and North American
financial community. 19 listed companies (biotech and medtech), among whom Erytech Pharma, DBV
Genomic Vision, Mauna Kea
Transgene and other major
actors on French Healthcare market, will showcase
to North American investors.
“19 potential world champions will represent our life sciences industry in front of an audience of specialized American investors! We are delighted about the interest spurred by “French Life Sciences Days,” which will take place for the first time in New York with the U.S. financial community. This event will be a fantastic opportunity for France. In our industry, finance is the friend of innovation and employment. Our companies were born with an international dimension, and they develop breakthrough innovations that are increasingly attractive to foreign investors. Our mature sector is the future of the pharmaceutical industry, which is increasingly turning to these innovations. It is a promising sector, whose strong growth worldwide promises a pool of opportunities for highly-skilled French workers. We thank the 19 companies and our partners (Bryan Garnier & Co., Société Générale, Invest Security, Deloitte and NewCap) who will participate in the event as experts in their respective sectors of business. This first edition is intended to be replicated in countries where it will be important for our companies to showcase their innovations and breakthroughs,” explained Pierre-Olivier Goineau, the president of France Biotech.
Garnier & Co is delighted to sponsor this first Edition of the French Life
Sciences Days. Every day through our New York office we are promoting European listed
healthcare companies to US investors. US investors have become a major component
of the follow-on offerings Bryan Garnier has bookrun in recent months. It is a
key success factor for French biotechs and medtechs to build-up a US
shareholder base that will recognize their scientific and value creation
potential and will accompany their development. Bryan Garnier & Co has
successfully helped a number of the companies participating in this event to have
top tier US investors as shareholders” , stated Olivier Garnier, Managing
Partner at Bryan, Garnier & Co.
For more information, please visit http://conf.france-biotech.org/france-biotech/french-conf
About France Biotech
France Biotech brings together the main French life science companies and their expert partners. Its mission is to support the development of the French life sciences by advocating for a favorable regulatory and fiscal environment. In 2004, France Biotech successfully lobbied the French government to create a special fiscal status for innovative start-ups and continues to act as an advocate for the French innovative sector. The organization is currently chaired by Pierre-Olivier Goineau, Co-Founder and CEO of ERYTECH Pharma. France Biotech has over 150 members and its board of directors is composed of 20 entrepreneurs in the life sciences.
About Bryan, Garnier & Co
Bryan, Garnier & Co is an international growth focused independent investment bank with operations in London, Paris, Geneva, New York and New Delhi. The firm employs 120 professionals and provides investment management, equity research, sales & trading and investment banking (private and public capital raising and M&A) services to growth companies and their investors, with a focus on the TMT, Healthcare, Renewable Energies & Environment, Specialty Retail and Business Services industry sectors. Bryan, Garnier & Co regularly keeps top spot in the European M&A and Equity Capital Markets league tables in Technology, Media Telecom and Healthcare sectors. The firm benefits from a strong recognition of its pan-European equity research activity which was awarded Most Productive European Broker for 2013 by Financial Times / Starmine. In April 2014, Bryan, Garnier & Co investment banking activities were awarded best investment bank of the year in TMT and Healthcare by Leaders League. Recently, Bryan, Garnier & Co led the largest healthcare IPO on NYSE Euronext in H1 2013, was joint lead manager and bookrunner of LDR Nasdaq IPO in October 2013, acted as sole manager of Transgene 65m€ PIPE, led one of the largest European private placement for Merieux Nutrisciences, and acted as lead manager of Erytech, Genomic Vision and McPhy Energy IPOs on NYSE Euronext. Bryan, Garnier & Co is a fully registered broker dealer authorized by the FCA in Europe and by the FINRA in the USA, is a member of the London Stock Exchange, a member of NYSE Euronext and a listing sponsor on Alternext. In April 2014, the firm announced a strategic alliance with City stockbroker Westhouse Securities to increase its presence on the UK domestic small cap market segment.